Author

J. M. Fehling

Observed institutions: Mayo Clinic, Exelixis (United States), Stanford University

OpenAlex ID: A5048040956

A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors

2008 · L. S. Rosen, P. Galatin, et al. · Journal of Clinical Oncology · 17

A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)

2008 · H. A. Wakelee, J. M. Fehling, et al. · Journal of Clinical Oncology · 12

A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies

2007 · H. A. Wakelee, J. R. Molina, et al. · Journal of Clinical Oncology · 6

A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM)

2007 · Julian R. Molina, Heather A. Wakelee, et al. · Molecular Cancer Therapeutics

Works count: 4

Citation count: 35

H-index: 3

I10-index: 2